SP-96 是一种高效、选择性和 ATP 竞争性 Aurora B 抑制剂，IC₅₀ 为 0.316 nM，对 FLT3 和 KIT 具有 >2000 倍选择性。SP-96 在 NCI60 筛选中表现出选择性生长抑制，对 MDA-MD-468 等乳腺癌细胞具有选择性 (GI₅₀=107 nM)。SP-96 可用于三阴性乳腺癌 (TNBC) 的相关研究。

SP-96 is a highly potent, selective and non-ATP-competitive Aurora B (IC 50 =0.316 nM) inhibitor and shows >2000 fold selectivity against FLT3 and KIT. SP-96 shows selective growth inhibition in NCI60 screening, incluing MDA-MD-468 (GI 50 =107 nM). SP-96 can be used for the research of triple negative breast cancer (TNBC).

Solid

Aurora A 18.975 nM (IC50) Aurora B 0.316 n

SP-96 is a highly potent, selective and non-ATP-competitive Aurora B (IC50=0.316 nM) inhibitor and shows >2000 fold selectivity against FLT3 (IC50=1475.6 nM) and KIT (IC50=1307.6 nM).
SP-96 (0-1 μM; 24 hours) is not promiscuous, rather selective for a few cell lines, it inhibits MDA-MB-468, CCRF-CEM, COLO 205 and A498 cell growth with GI50 values of 107 nM,47.4 nM, 50.3 nM and 53.2 nM, respectively.
SP-96 (63.2 nM) inhibits Aurora B activity in H460 cells by the characteristics of increased DNA content, and it increases cell volume with enormous nucleus.
SP-96 (0-2 μM) inhibits Aurora B enzymatic activity with an IC50 of 0.316 nM and inhibits Aurora A with observed IC50 value of 18.975 nM. SP-96 shows >2000 fold selectivity against FLT3 (IC50=1475.6 nM)

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. Naga Rajiv Lakkaniga,et al. Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression.Eur J Med Chem. 2020 Jul 12;203:112589.

In Vitro: DMSO : 100 mg/mL (220.52 mM; Need ultrasonic)配制储备液